ADAPTIVE BIOTECHNOLOGIES CORPORATION - COMMON STOC

12,80

26-августа-25 13:45:00

15 мин. задержка

Акции

+0,13

+1,03%

Сегодняшний диапазон

12,62 - 12,85

ISIN

N/A

Источник

NASDAQ

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

05 авг 2025 13:05:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025

15 июл 2025 13:05:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

01 июл 2025 04:30:07 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

30 май 2025 04:30:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

28 май 2025 13:05:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

01 май 2025 13:05:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

10 апр 2025 13:05:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

08 апр 2025 05:00:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

11 мар 2025 05:00:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

11 фев 2025 13:05:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

05 фев 2025 13:05:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

22 янв 2025 13:05:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

14 янв 2025 04:30:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

07 янв 2025 04:30:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

02 янв 2025 13:05:00 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

07 дек 2024 15:30:22 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

03 дек 2024 04:30:25 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results

07 ноя 2024 13:05:01 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

07 ноя 2024 04:30:55 Источник Nasdaq GlobeNewswire
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

09 окт 2024 13:05:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.